What was Zelira Therapeutics’s price range in the past 12 months?
Zelira Therapeutics lowest stock price was $0.16 and its highest was $1.33 in the past 12 months.
What is Zelira Therapeutics’s market cap?
Currently, no data Available
When is Zelira Therapeutics’s upcoming earnings report date?
Zelira Therapeutics’s upcoming earnings report date is Aug 29, 2024 which is in 42 days.
How were Zelira Therapeutics’s earnings last quarter?
Zelira Therapeutics released its earnings results on Feb 22, 2024. The company reported -$2.037 earnings per share for the quarter, missing the consensus estimate of N/A by -$2.037.
Zelira Therapeutics does not currently pay dividends.
What is Zelira Therapeutics’s EPS estimate?
Zelira Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zelira Therapeutics have?
Zelira Therapeutics has 11,347,155 shares outstanding.
What happened to Zelira Therapeutics’s price movement after its last earnings report?
Zelira Therapeutics reported an EPS of -$2.037 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Zelira Therapeutics?
Currently, no hedge funds are holding shares in ZLDAF
Zelira Therapeutics Ltd, formerly Zelda Therapeutics Ltd is an Australia-based biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema; and a pre-clinical research program to examine the effect of cannabinoids in a breast, brain, and pancreatic cancer.